| Literature DB >> 30109192 |
Jian Bai1, Rong Mu1, Man Dou1, Daojiang Yan1, Bingyu Liu1, Qian Wei1, Jun Wan1, Yi Tang1,2, Youcai Hu1.
Abstract
Epigenetic modifications have been proved to be a powerful way to activate silent gene clusters and lead to diverse secondary metabolites in fungi. Previously, inactivation of a histone H3 deacetylase in Calcarisporium arbuscula had led to pleiotropic activation and overexpression of more than 75% of the biosynthetic genes and isolation of ten compounds. Further investigation of the crude extract of C. arbuscula ΔhdaA strain resulted in the isolation of twelve new diterpenoids including three cassanes (1-3), one cleistanthane (4), six pimaranes (5-10), and two isopimaranes (11 and 12) along with two know cleistanthane analogues. Their structures were elucidated by extensive NMR spectroscopic data analysis. Compounds 2 and 4 showed potent inhibitory effects on the expression of MMP1 and MMP2 (matrix metalloproteinases family) in human breast cancer (MCF-7) cells.Entities:
Keywords: Calcarisporic acids; Calcarisporium arbuscula; Diterpenoid; Epigenetic genome mining; Matrix metalloproteinases inhibitor; Pimarane
Year: 2018 PMID: 30109192 PMCID: PMC6090014 DOI: 10.1016/j.apsb.2017.12.012
Source DB: PubMed Journal: Acta Pharm Sin B ISSN: 2211-3835 Impact factor: 11.413
Figure 1Structures of compounds 1—14.
13C NMR spectroscopic data (δ) for compounds 1−12a (δ in ppm).
| No. | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 28.2 | 29.21 | 71.1 | 28.6 | 25.9 | 25.6 | 31.1 | 30.8 | 31.6 | 28.4 | 31.3 | 30.0 |
| 2 | 24.3 | 26.3 | 26.45 | 26.0 | 27.7 | 27.8 | 20.1 | 20.1 | 27.7 | 19.7 | 27.7 | 20.0 |
| 3 | 79.4 | 73.2 | 26.43 | 72.9 | 73.7 | 73.8 | 32.8 | 32.9 | 71.3 | 33.5 | 71.4 | 32.9 |
| 4 | 59.3 | 49.1 | 48.6 | 51.0 | 51.1 | 51.2 | 49.7 | 49.8 | 48.7 | 50.4 | 49.0 | 49.9 |
| 5 | 82.2 | 78.9 | 77.7 | 78.0 | 80.5 | 80.1 | 77.1 | 76.9 | 46.5 | 81.2 | 46.7 | 76.9 |
| 6 | 211.7 | 69.8 | 27.8 | 69.2 | 26.4 | 26.4 | 26.3 | 26.3 | 21.3 | 30.0 | 21.7 | 26.8 |
| 7 | 42.0 | 32.7 | 24.2 | 35.0 | 26.8 | 26.7 | 27.2 | 27.1 | 31.4 | 27.8 | 32.0 | 26.7 |
| 8 | 39.1 | 29.17 | 33.5 | 35.4 | 128.8 | 128.1 | 129.0 | 128.2 | 129.8 | 137.5 | 128.7 | 128.0 |
| 9 | 35.8 | 35.8 | 29.3 | 45.8 | 138.8 | 138.5 | 139.2 | 139.2 | 140.5 | 78.5 | 140.3 | 137.9 |
| 10 | 45.2 | 41.6 | 42.8 | 41.1 | 44.6 | 44.6 | 44.4 | 44.6 | 39.4 | 43.4 | 39.2 | 44.4 |
| 11 | 26.9 | 24.9 | 24.4 | 26.6 | 22.1 | 22.2 | 22.1 | 22.1 | 21.7 | 27.6 | 22.0 | 22.6 |
| 12 | 128.8 | 129.3 | 128.7 | 35.7 | 30.1 | 31.6 | 30.2 | 31.5 | 32.3 | 32.9 | 27.6 | 28.4 |
| 13 | 142.6 | 141.5 | 141.1 | 151.0 | 40.6 | 41.1 | 40.6 | 41.1 | 40.7 | 40.0 | 40.4 | 40.4 |
| 14 | 33.2 | 31.6 | 31.6 | 53.6 | 77.2 | 88.5 | 77.2 | 88.6 | 77.9 | 132.8 | 76.0 | 76.3 |
| 15 | 14.8 | 15.0 | 14.6 | 139.8 | 145.8 | 146.4 | 145.8 | 146.3 | 147.7 | 146.6 | 147.9 | 147.5 |
| 16 | 139.6 | 139.0 | 138.7 | 116.7 | 112.3 | 112.3 | 112.3 | 112.4 | 111.8 | 113.7 | 111.8 | 112.0 |
| 17 | 110.5 | 110.1 | 109.6 | 106.2 | 23.0 | 21.8 | 22.9 | 21.9 | 19.6 | 29.7 | 21.1 | 21.5 |
| 18 | 19.4 | 20.6 | 24.0 | 19.9 | 20.4 | 20.5 | 24.5 | 24.5 | 24.6 | 24.2 | 24.6 | 24.6 |
| 19 | 175.1 | 178.4 | 179.0 | 177.5 | 178.7 | 178.9 | 181.0 | 181.1 | 181.3 | 180.2 | 181.4 | 181.2 |
| 20 | 15.5 | 15.1 | 14.5 | 15.0 | 22.9 | 22.9 | 22.6 | 22.6 | 17.9 | 19.2 | 17.9 | 22.5 |
| OMe | 62.0 | 62.1 |
NMR data (δ) were measured at 125 MHz in CD3OD for 1, 5, 6, 8−12; at 150 MHz in CD3OD for 7; and at 150 MHz in DMSO-d6 for 2−4.
1H NMR spectroscopic data (δ) for compounds 1−4a (δ in ppm, J in Hz).
| No. | ||||
|---|---|---|---|---|
| 1 | 1.94, overlap | 1.70, td (13.8, 3.5) | 3.57, d (3.0) | 1.66, overlap |
| 1.59, m | 1.14, d (12.5) | 1.26, br d (12.8) | ||
| 2 | 2.31, m | 1.98, overlap | 2.10, overlap | 1.98, overlap |
| 2.03, overlap | 1.56, d (11.6) | 1.64, overlap | 1.57, m | |
| 3 | 4.34, br d (5.5) | 4.22, br s | 1.72, td (13.7, 4.0) | 5.21, br s |
| 1.50, overlap | ||||
| 6 | 4.04, br s | 2.03, td (13.8, 2.4) | 3.92, br s | |
| 1.62, overlap | ||||
| 7 | 3.14, t (12.9) | 2.11, m | 1.87, overlap | 1.62, overlap |
| 2.09, dd (13.0, 4.9) | 1.35, overlap | 1.24, br d (12.1) | ||
| 8 | 1.94, overlap | 1.77, m | 1.52, overlap | 1.41, m |
| 9 | 2.71, m | 2.09, m | 2.56, m | 1.72, overlap |
| 11 | 2.22, m | 2.01, overlap | 2.12, overlap | 1.70, overlap |
| 2.02, overlap | 1.95, overlap | 1.84, overlap | 1.00, qd (13.0, 3.6) | |
| 12 | 5.66, br s | 5.63, t (3.5) | 5.63, t (3.8) | 2.35, d (12.9) |
| 1.98, overlap | ||||
| 14 | 2.47, m | 2.32, m | 2.38, m | 2.25, t (9.8) |
| 15 | 1.08, d (7.0) | 0.87, d (6.8) | 0.92, d (6.9) | 5.62, ddd (17.2, 9.8, 9.8) |
| 16 | 6.25, dd (17.7, 10.9) | 6.20, dd (17.6, 10.9) | 6.20, dd (17.6, 10.9) | 5.13, dd (10.2, 2.0) |
| 4.98, dd (17.2, 2.0) | ||||
| 17 | 5.09,d (17.7) | 5.08,d (17.6) | 5.07,d (17.6) | 4.64, d (1.1) |
| 4.92, d (10.9) | 4.90, d (10.9) | 4.89, d (10.9) | 4.48, br s | |
| 18 | 1.50, s | 1.36, s | 1.12, s | 1.32, s |
| 20 | 0.89, s | 0.96, s | 0.70, s | 0.91, s |
| 1-OH | 5.50, d (4.0) | |||
| 3-OH | 6.23, br s | 6.23, d (2.5) | ||
| 5-OH | 6.10, br s | 5.15, s | 6.20, br s | |
| 6-OH | 7.21, br s | |||
| 19-OH | 12.11, s | 14.32, br s |
NMR data (δ) were measured at 500 MHz in CD3OD for 1 and at 600 MHz in DMSO-d6 for 2−4.
Figure 21H—1H COSY and key HMBC correlations of compounds 1, 4, 5 and 10.
Figure 3Key NOESY correlations of compounds 1, 4, 5 and 11.
Figure 4CD spectrum of 1 in MeOH.
1H NMR spectroscopic data (δ) for compounds 5−8a (δ in ppm, J in Hz).
| No. | ||||
|---|---|---|---|---|
| 1 | 1.97, overlap | 1.96, overlap | 1.78, dd (12.9, 4.1) | 1.77, overlap |
| 1.41, br d (12.5) | 1.38, overlap | 1.42, overlap | 1.41, overlap | |
| 2 | 2.31, m | 2.30, m | 1.97, overlap | 1.96, overlap |
| 1.73, dd (14.4, 3.0) | 1.71, m | 1.46, overlap | 1.45, overlap | |
| 3 | 4.10, br s | 4.07, br s | 1.83, d (12.7) | 1.83, d (12.8) |
| 1.74, overlap | 1.72, overlap | |||
| 6 | 2.48, m | 2.47, m | 2.49, m | 2.50, m |
| 1.92, overlap | 1.94, overlap | 1.93, overlap | 1.94, overlap | |
| 7 | 2.55, m | 2.51, m | 2.57, m | 2.51, m |
| 1.93, overlap | 1.93, overlap | 1.95, overlap | 1.96, overlap | |
| 11 | 2.02, overlap | 1.99, overlap | 1.94, overlap | 1.92, overlap |
| 1.96, overlap | 1.94, overlap | |||
| 12 | 1.67, m | 1.59, m | 1.66, m | 1.58, m |
| 1.44, overlap | 1.47, overlap | 1.43, overlap | 1.46, overlap | |
| 14 | 3.47, br s | 3.24, br s | 3.48, br s | 3.24, br s |
| 15 | 5.76, dd (17.7, 11.0) | 5.80, dd (17.7, 11.0) | 5.77, dd (17.7, 11.0) | 5.80, dd (17.7, 11.0) |
| 16 | 4.96, br d (17.7) | 4.99, dd (17.7, 1.4) | 4.96, dd (17.7, 1.4) | 4.99, dd (17.7, 1.0) |
| 4.93, br d (11.0) | 4.95, dd (11.0, 1.4) | 4.94, dd (10.9, 1.4) | 4.95, dd (11.0, 1.0) | |
| 17 | 1.01, s | 1.05, s | 1.01, s | 1.05, s |
| 18 | 1.46, s | 1.45, s | 1.23, s | 1.24, s |
| 20 | 1.01, s | 1.01, s | 1.00, s | 1.00, s |
| OMe | 3.51, s | 3.52, s |
NMR data (δ) were measured at 500 MHz in CD3OD for 5, 6, and 8, and at 600 MHz in CD3OD for 7.
1H NMR spectroscopic data (δ) for compounds 9−12a (δ in ppm, J in Hz).
| No. | ||||
|---|---|---|---|---|
| 1 | 1.56, overlap | 1.61, dd (13.6, 3.7) | 1.54, overlap | 1.76, overlap |
| 1.52, overlap | 1.31, br d (13.6) | 1.45, overlap | ||
| 2 | 2.17, m | 1.99, dd (13.5, 3.8) | 2.19, m | 1.98, overlap |
| 1.63, m | 1.48, overlap | 1.63, dd (14.4, 3.0) | 1.45, overlap | |
| 3 | 4.00, t (2.50) | 1.88, d (14.0) | 4.01, br s | 1.85, d (13.2) |
| 1.52, overlap | 1.69, m | |||
| 5 | 1.79, d (12.2) | 1.79, dd (9.3, 3.9) | ||
| 6 | 1.90, overlap | 2.54, td (13.9, 6.0) | 2.02, overlap | 2.45, overlap |
| 1.84, td (12.1, 5.3) | 1.92, dd (14.7, 5.2) | 1.90, overlap | 1.95, overlap | |
| 7 | 2.34, m | 2.32, tdd (13.5, 5.8, 2.2) | 2.47, br d (13.5) | 2.43, overlap |
| 1.95, dd (18.0, 4.5) | 2.22, dd (15.5, 4.9) | 1.86, overlap | 2.08, overlap | |
| 11 | 2.07, m | 1.71, m | 2.03, overlap | 2.02, overlap |
| 1.92, overlap | 1.50, overlap | 1.91, overlap | 1.93, overlap | |
| 12 | 1.57, overlap | 1.59, overlap | 1.73, m | 1.74, m |
| 1.43, m | 1.49, overlap | 1.36, br d (12.3) | 1.38, dd (12.9, 5.0) | |
| 14 | 3.63, br s | 5.37, br s | 3.22, br s | 3.30, br s |
| 15 | 5.86, dd (17.7, 10.9) | 5.70, dd (17.4, 10.5) | 6.00, dd (18.0, 10.5) | 6.01, dd (17.4, 10.4) |
| 16 | 4.98, dd (17.7, 1.1) | 4.96, dd (10.5, 1.7) | 5.00, dd (18.0, 1.0) | 5.01, dd (17.4, 1.5) |
| 4.94, dd (10.9, 1.1) | 4.91, dd (17.4, 1.7) | 4.99, dd (10.5, 1.0) | 5.00, dd (10.4, 1.5) | |
| 17 | 0.98, s | 1.03, s | 0.89, s | 0.92, s |
| 18 | 1.27, s | 1.28, s | 1.28, s | 1.23, s |
| 20 | 0.92, s | 0.95, s | 0.96, s | 1.06, s |
NMR data (δ) were measured at 500 MHz in CD3OD for 9−12.
Scheme 1Proposed biosynthetic pathways for compounds 1−14.
Figure 5Effects of compounds 2, 4, 6, and 7 on the expressions of MMP1 and MMP2 in MCF-7 cells. (A) Cells were treated with different test compounds at 200 μmol/L or DMSO as control for 24 h. The expressions of MMP1 and MMP2 were determined by Western blot. Representative immunoblots are shown and GAPDH is the loading control. (B) Relative expression level of MMP1 is calibrated by GAPDH. (C) Relative expression level of MMP2 is calibrated by GAPDH. Each value represents the mean±SD of three independent experiments. *P<0.05, **P<0.01 versus DMSO control.